The benefits of anti-VEGF therapy, including the possibility of reduced permanent peripheral visual field loss, reduced anterior segment abnormalities, and less myopia [18] have made anti-VEGF therapy the preferred mode for many ROP patients. This evidence concerns the gene VEGFA and retinopathy of prematurity.